Skin Thickness Progression Rate: a Predictor of Mortality and Early Internal Organ Involvement in Diffuse Scleroderma

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2010 Aug 4

PMID 20679474

Citations 79

Authors

Robyn T Domsic

Tatiana Rodriguez-Reyna

Mary Lucas

Noreen Fertig

Thomas A Medsger Jr

Affiliations

Soon will be listed here.

Abstract

Objective: To examine the association of skin thickness progression rate (STPR) with mortality, and as a predictor of future internal organ involvement in an inception cohort of diffuse cutaneous systemic sclerosis (SSc) patients.

Methods: Diffuse cutaneous SSc patients older than 16 years of age evaluated at the University of Pittsburgh within 2 years of the first evidence of skin thickening between 1980 and 2005 were eligible. The authors calculated the STPR on these patients, and examined the relationship of this variable to the development of early internal organ involvement and short-term mortality using logistic regression.

Results: 826 patients were included in the analysis. Patients with a rapid STPR experienced significantly reduced short-term survival at 1 and 2 years from the time of first Pittsburgh evaluation (p=0.002). Patients with a rapid STPR were more likely to develop renal crisis within 1-2 years of follow-up. Rapid STPR was found to be an independent predictor of both mortality (OR 1.72; 95% CI 1.13 to 2.62; p=0.01) and 'renal crisis' (OR 2.05, 95% CI 1.10 to 3.85; p=0.02) within 2 years from first evaluation.

Conclusion: The STPR is an easy measure to perform at the time of initial evaluation for identifying those diffuse cutaneous SSc patients who are at increased risk of mortality and the development of renal crisis during the following 2 years.

Citing Articles

Incidence of secondary pericardial effusions associated with different etiologies: a comprehensive review of literature.

Ebrahimi P, Taheri H, Bahiraie P, Rader F, Siegel R, Mandegar M J Cardiothorac Surg. 2025; 20(1):141.

PMID: 39987086 PMC: 11846477. DOI: 10.1186/s13019-025-03370-5.

Skin ultrasound for rheumatologists: Technical issues and challenges.

Micu M, Wortsman X, Naredo E J Scleroderma Relat Disord. 2024; :23971983241289236.

PMID: 39544901 PMC: 11559526. DOI: 10.1177/23971983241289236.

Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents.

Papa N, Cavalli S, Rindone A, Onida F, Saporiti G, Minniti A Arthritis Res Ther. 2024; 26(1):182.

PMID: 39444017 PMC: 11515700. DOI: 10.1186/s13075-024-03408-4.

Comorbidity burden on mortality in patients with systemic sclerosis.

Fauthoux T, Brisou D, Lazaro E, Seneschal J, Constans J, Skopinski S RMD Open. 2024; 10(4).

PMID: 39424406 PMC: 11492939. DOI: 10.1136/rmdopen-2024-004637.

The diagnostic value and clinical relevance of high frequency ultrasound and shear wave elastography in systemic sclerosis: an observational monocentric study.

Yu S, Peng H, Yang X, Ma S, Yu J, Zuo D Clin Rheumatol. 2024; 43(12):3759-3769.

PMID: 39367267 PMC: 11582183. DOI: 10.1007/s10067-024-07145-6.

References

Jacobsen S, Ullman S, Shen G, Wiik A, Halberg P . Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol. 2001; 28(11):2454-9. View

Tyndall A, Bannert B, Vonk M, Airo P, Cozzi F, Carreira P . Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69(10):1809-15. DOI: 10.1136/ard.2009.114264. View

Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black C . Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum. 2007; 56(7):2422-31. DOI: 10.1002/art.22721. View

Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M . Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986; 13(5):911-6. View

Medsger Jr T, MASI A . Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis. 1973; 26(10):647-60. DOI: 10.1016/0021-9681(73)90054-4. View

Wynn J, Fineberg N, Matzer L, Cortada X, Armstrong W, Dillon J . Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J. 1985; 110(1 Pt 1):123-7. DOI: 10.1016/0002-8703(85)90525-3. View

Altman R, Medsger Jr T, Bloch D, Michel B . Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991; 34(4):403-13. DOI: 10.1002/art.1780340405. View

Barnett A, Miller M, Littlejohn G . A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol. 1988; 15(2):276-83. View

Clements P, Hurwitz E, Wong W, Seibold J, Mayes M, White B . Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum. 2000; 43(11):2445-54. DOI: 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q. View

10.

Bennett R, Bluestone R, Holt P, Bywaters E . Survival in scleroderma. Ann Rheum Dis. 1971; 30(6):581-8. PMC: 1005833. DOI: 10.1136/ard.30.6.581. View

11.

Czirjak L, Kumanovics G, Varju C, Nagy Z, Pakozdi A, Szekanecz Z . Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis. 2007; 67(1):59-63. DOI: 10.1136/ard.2006.066340. View

12.

Lee P, Langevitz P, Alderdice C, Aubrey M, Baer P, Baron M . Mortality in systemic sclerosis (scleroderma). Q J Med. 1992; 82(298):139-48. View

13.

Nagy Z, Czirjak L . Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol. 1997; 16(5):454-60. DOI: 10.1007/BF02238937. View

14.

Steen V, Medsger Jr T, Osial Jr T, Ziegler G, Shapiro A, Rodnan G . Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med. 1984; 76(5):779-86. DOI: 10.1016/0002-9343(84)90986-0. View

15.

Vlachoyiannopoulos P, Dafni U, Pakas I, Spyropoulou-Vlachou M, Stavropoulos-Giokas C, Moutsopoulos H . Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis. 2000; 59(5):359-67. PMC: 1753131. DOI: 10.1136/ard.59.5.359. View

16.

Medsger Jr T, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W . Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003; 21(3 Suppl 29):S42-6. View

17.

Hesselstrand R, Scheja A, Akesson A . Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis. 1999; 57(11):682-6. PMC: 1752504. DOI: 10.1136/ard.57.11.682. View

18.

Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G . Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002; 81(2):139-53. DOI: 10.1097/00005792-200203000-00004. View

19.

White B, Bauer E, Goldsmith L, Hochberg M, Katz L, Korn J . Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum. 1995; 38(3):351-60. DOI: 10.1002/art.1780380309. View

20.

Bryan C, Howard Y, Brennan P, Black C, Silman A . Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol. 1996; 35(11):1122-6. DOI: 10.1093/rheumatology/35.11.1122. View